Immunosuppression in solid-organ transplantation essentials and practical tips

Critical Care Nursing Quarterly

Volumn 39, Issue 3, 2016, Pages 227-240

  Jasiak, Natalia M ^a   Park, Jeong M ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Immunosuppression; Nursing; Organ transplantation; Patient education

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BASILIXIMAB; BELATACEPT; CORTICOSTEROID; CYCLOSPORIN; EVEROLIMUS; IMMUNOGLOBULIN; MYCOPHENOLATE MOFETIL; MYCOPHENOLIC ACID; PREDNISONE; RAPAMYCIN; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; CAREGIVER; CORTICOSTEROID THERAPY; DRUG MONITORING; DRUG PULSE THERAPY; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAINTENANCE THERAPY; ORGAN TRANSPLANTATION; PATIENT CARE; PATIENT EDUCATION; PATIENT MONITORING; TREND STUDY; DRUG INTERACTION; HISTOCOMPATIBILITY; INTENSIVE CARE NURSING; NURSING; PRACTICE GUIDELINE; PROCEDURES;

CRITICAL CARE NURSING; DRUG INTERACTIONS; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION; PRACTICE GUIDELINES AS TOPIC; TRANSPLANTATION IMMUNOLOGY;

EID: 84980041550     PISSN: 08879303     EISSN: 15505111     Source Type: Journal    
DOI: 10.1097/CNQ.0000000000000117     Document Type: Article

References (41)

1. Lee RA, Gabardi S. Current trends in immunosuppressive therapies for renal transplant recipients. Am J Health-Syst Pharm. 2012;69: 1961-1975.
2. Matas AJ, Smith JM, Skeans MA, et al. OPTN/SRTR 2012 annual data report. Am J Transplant. 2014; 14(suppl 1): S11-S44.
3. Wagner SJ, Brennan DC. Induction therapy in renal transplant recipients. How convincing is the current evidence? Drugs. 2012;72: 671-683.
4. Cai J, Terasaki PI. Induction immunosuppression improves long-term graft and patient outcome in organ transplantation: An analysis of United Network for Organ Sharing Registry Data. Transplantation. 2010;90: 1511-1515.
5. Hardinger KL. Rabbit antithymocyte globulin induction therapy in adult renal transplantation. Pharmacotherapy. 2006;26(12): 1771-1783.
6. Marvin MR, Droogan C, Sawinski D, Cohen DJ, Hardy MA. Administration of rabbit antithymocyte globulin (thymoglobulin) in ambulatory renal-transplant patients. Transplantation. 2003;75(4): 488-489.
7. Wiland AM, Fink JC, Philosophe B, et al. Peripheral administration of thymoglobulin for induction therapy in pancreas transplantation. Transplant Proc. 2001;33(1/2): 1910.
8. Simulect [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2009.
9. Campath [package insert]. Cambridge, MA: Genzyme Corporation; 2014.
10. Ciancio G, Gaynor JJ, Guerra G, et al. Randomized trial of three induction antibodies in kidney transplantation: Long-term results. Transplantation. 2014;97(11): 1128-1138.
11. Pirsch JD, Henning AK, First MR, et al. New-onset diabetes after transplantation: Results from a doubleblind early corticosteroid withdrawal trial. Am J Transplant. 2015;15(7): 1982-1990.
12. Liefeldt L, Buddle K. Risk factors for cardiovascular disease in renal transplant recipients and strategies to minimize risk. Transplant Int. 2010;23(12): 1191-1204.
13. Woodle ES, First MR, Pirsch J, et al. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg. 2008;248(4): 564-577.
14. Rike AH, Mogilishetty G, Alloway RR, et al. Cardiovascular risk, cardiovascular events, and metabolic syndrome in renal transplantation: Comparison of early steroid withdrawal and chronic steroids. Clin Transplant. 2008;22(2): 229-235.
15. Ahsan N, Hricik D, Matas A, et al. Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil-A prospective randomized study. Transplantation. 1999; 68(12): 1865-1874.
16. Starzl TE, Weil R, Iwatsuki S, et al. The use of cyclosporine A and prednisolone on cadaver kidney transplantation. Surg Gynecol Obstet. 1980;151: 17-26.
17. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007;357: 2562-2575.
18. Astagraf XL [package insert]. Northbrook, IL: Astellas Pharma Inc; 2015.
19. Tremblay S, Alloway RR, Young S, et al. A steady-state pharmacokinetic comparison of all FK-506 formulations (ASTCOFF study): An open label, prospective, randomized, two arm, three period crossover study. Paper presented at: Congress of the European Society of Organ Transplantation; September 13-16, 2015; Brussels, Belgium. Abstract 416.
20. Envarsus XR [package insert]. Edison, NJ: Veloxis Pharmaceuticals; 2015.
21. Pennington CA, Park JM. Sublingual tacrolimus as an alternative to oral administration for solid organ transplant recipients. Am J Health-Syst Pharm. 2015;72(4): 277-284.
22. Doligalski CT, Liu EC, Sammons CM, Silverman A, Logan AT. Sublingual administration of tacrolimus: Current trends and available evidence. Pharmacotherapy. 2014;34: 1209-1219.
23. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003;349: 931-940.
24. Imuran [package insert]. Hunt Valley, MD: Pharmaceutics International; 2014.
25. Myfortic [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2013.
26. Mycophenolate REMS. https://www.mycophenola terems.com. Accessed October 27, 2015.
27. Rapamune [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals; 2008.
28. Zortress [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2015.
29. Afinitor Disperz [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2015.
30. Nulojix [package insert]. Princeton, NJ: Bristol- Meyers Squibb Company; 2014.
31. Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant. 2010;10(3): 535-546.
32. Vincenti F, Grinyo J, Rostain L, et al. Belatacepttreated patients had better graft survival at 7-years post-transplant compared with cyclosporine-treated patients: Final results from BENEFIT. Paper presented at: American Transplant Congress; May 6, 2015; Philadelphia, PA. Abstract 452.
33. Durrbach A, Pestana JM, Pearson T, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFITEXT study). Am J Transplant. 2010;10(3): 547-557.
34. Belatacept REMS. http://www.nulojix.com/hcp/rems .aspx. Accessed October 27, 2015.
35. Haas M, Sis B, Racusen LC, et al. Banff 2013 meeting report: Inclusion of C4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant. 2014;2: 272-283.
36. Jordan SC, Tyan D, Stablein D, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: Report of the NIH IG02 Trial. J Am Soc Nephrol. 2004;15: 3256-3262.
37. Nurse's Drug Handbook. Sudbury, MA: Jones & Bartlett Publishers; 2009: 521-525.
38. Barnett AN, Jadjianastassiou VG, Mamode N. Rituximab in renal transplantation. Transplant Int. 2013;26(6): 563-575.
39. Rituximab [package insert]. San Francisco, CA: Genentech Inc; 2014.
40. Kamar N, Milioto O, Puissant-Lubrano B, et al. Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant recipients. Am J Transplant. 2010;10(1): 89-98.
41. Grim SA, Pham T, Thielke J, et al. Infectious complications associated with the use of rituximab for ABO-incompatible and positive cross-match renal transplant recipients. Clin Transplant. 2007;21(5): 628-632.